MXPA05006042A - Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores. - Google Patents

Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.

Info

Publication number
MXPA05006042A
MXPA05006042A MXPA05006042A MXPA05006042A MXPA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A MX PA05006042 A MXPA05006042 A MX PA05006042A
Authority
MX
Mexico
Prior art keywords
dendritic cells
tumor
administration
cells
tumor treatment
Prior art date
Application number
MXPA05006042A
Other languages
English (en)
Spanish (es)
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of MXPA05006042A publication Critical patent/MXPA05006042A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA05006042A 2002-12-06 2003-12-05 Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores. MXPA05006042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (1)

Publication Number Publication Date
MXPA05006042A true MXPA05006042A (es) 2005-09-21

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006042A MXPA05006042A (es) 2002-12-06 2003-12-05 Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.

Country Status (18)

Country Link
US (2) US20060057120A1 (https=)
EP (2) EP1567155B1 (https=)
JP (2) JP4859169B2 (https=)
KR (1) KR101144196B1 (https=)
CN (2) CN102600461B (https=)
AT (1) ATE486125T1 (https=)
AU (2) AU2003293411B2 (https=)
BR (1) BRPI0317064B8 (https=)
CA (1) CA2509058A1 (https=)
DE (1) DE60334725D1 (https=)
DK (1) DK1567155T3 (https=)
ES (1) ES2354944T3 (https=)
IL (1) IL169002A (https=)
MX (1) MXPA05006042A (https=)
PL (1) PL377209A1 (https=)
PT (1) PT1567155E (https=)
RU (1) RU2348418C2 (https=)
WO (1) WO2004053072A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
RU2361598C1 (ru) * 2008-02-18 2009-07-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, индуцирующее созревание дендритных клеток
CA2718438C (en) * 2008-03-27 2021-06-29 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
EP3150703A1 (en) * 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
PL2534242T3 (pl) * 2010-02-10 2016-11-30 Polepszona kompozycja do hamowania proliferacji komórek nowotworowych
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
IL256522B2 (en) 2015-06-30 2024-10-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
CN116637180A (zh) * 2022-02-15 2023-08-25 沈阳药科大学 萜类化合物在提高其淋巴靶向作用中的应用
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69840739D1 (de) * 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CA2343355A1 (en) * 1998-09-15 2000-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
EP1126023A4 (en) * 1998-10-02 2005-02-16 Mitsubishi Chem Corp METHOD FOR THE INDUCTION OF CELLULAR IMMUNITY AND CELLS WITH INDUCED CELLULAR IMMUNITY
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
CN1367688A (zh) * 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US7405076B2 (en) * 2000-11-14 2008-07-29 Universite Libre De Bruxelles Generation and use of dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов

Also Published As

Publication number Publication date
KR20050084189A (ko) 2005-08-26
KR101144196B1 (ko) 2012-05-21
JP2006510667A (ja) 2006-03-30
EP1567155A2 (en) 2005-08-31
ES2354944T3 (es) 2011-03-21
RU2348418C2 (ru) 2009-03-10
WO2004053072A2 (en) 2004-06-24
JP4859169B2 (ja) 2012-01-25
AU2011200352B2 (en) 2013-06-27
US20120251561A1 (en) 2012-10-04
EP2260861A1 (en) 2010-12-15
BRPI0317064B1 (pt) 2020-11-03
CA2509058A1 (en) 2004-06-24
RU2005121256A (ru) 2006-02-10
CN102600461B (zh) 2017-07-14
AU2003293411A1 (en) 2004-06-30
HK1082180A1 (en) 2006-06-02
DE60334725D1 (de) 2010-12-09
BR0317064A (pt) 2005-10-25
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
US20060057120A1 (en) 2006-03-16
PT1567155E (pt) 2011-01-28
CN102600461A (zh) 2012-07-25
AU2003293411B2 (en) 2010-10-28
AU2011200352A1 (en) 2011-02-17
JP2011246493A (ja) 2011-12-08
IL169002A (en) 2015-01-29
BRPI0317064B8 (pt) 2021-05-25
DK1567155T3 (da) 2011-02-14
WO2004053072A3 (en) 2005-06-16
ATE486125T1 (de) 2010-11-15
PL377209A1 (pl) 2006-01-23
EP1567155B1 (en) 2010-10-27
CN1738619A (zh) 2006-02-22
JP5707284B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
MXPA05006042A (es) Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
Osborn Changes in BCG strains
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
ES2180758T3 (es) Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
ATE444738T1 (de) Verbesserte essbare filmformulierungen mit maltodextrin
MXPA05008342A (es) Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas.
DE60142683D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
UY26182A1 (es) Prevención y tratamiento de la enfermedad amiloidogenica
GB0109297D0 (en) Vaccine
AR106496A1 (es) Células dendríticas activadas de un modo óptimo, que inducen una respuesta inmunitaria antitumoral mayor o mejorada
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
EP1385541A4 (en) IMMUNOSTIMULATING COMBINATIONS CONTAINING AMINO ALKYL GLUCOSAMINE IDEPHOSPHATE AND QS-21
WO2002088328A8 (en) Method for generating highly active human dendritic cells from monocytes
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
RU2012136724A (ru) Лечение или профилактика инфекции
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
AR036355A1 (es) Modelo de exposicion a mycoplasma bovis, para evaluar la eficacia de potenciales vacunas
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
AR038699A1 (es) Vacunas anti-tumorales y metodos
Colon Jr Improving the appearance of severely fluorosed teeth
Lewandowska-Furmanik et al. TH1/TH2 balance in the subretinal fluid of patients with rhegmatogenous retinal detachment
NAIRN I Reader Abstract Service
Swanson Jr et al. Dr. Arstone and Gastronomic France: Gimme a Pigfoot and a Bottle of Beer

Legal Events

Date Code Title Description
FG Grant or registration